Global Kinetics adds former EMA head to board
Global Kinetics Corporation has appointed former EMA chief Dr Thomas Lönngren to its board, as it seeks to commercialise its Parkinson’s KinetiGraph (PKG) technology.
Lönngren is a Swedish regulatory affairs veteran with a background in health systems, drug and medical device regulations.
Global Kinetics has made the appointment as part of its EU expansion strategy for PKG, a device for monitoring Parkinson’s symptoms and helping to optimise treatment options.
The company also revealed it has been awarded a key European patent covering its intellectual property. The patent covers the company’s ability to record, measure and assess clinical movement data using the PKG technology, and the mathematical algorithms associated with the data analysis.
Global Kinetics CEO Andrew Maxwell said the two developments will be key to the company’s long-term plans for the device.
“Dr Lönngren has an impeccable background in health systems, drug, medical device regulations and in working with international government and industry stakeholders at the highest levels,” he said.
“We expect his expertise to prove invaluable as we deliver value for people with Parkinson’s disease, clinicians, governments and commercial stakeholders worldwide.”
The PKG already has clearance from the FDA, EMA and TGA.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
